COHR Bears Hold Their Ground Into a 44% Weekly Rally
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Coherent Corp. arrives at its August 12 earnings report having added another leg to an extraordinary run — the stock closed Friday at $379.13, up 44% on the week and 13% on Thursday alone — yet short sellers remain dug in rather than retreating.
Since the previous ORTEX note published Tuesday, the short picture has shifted modestly but the thesis holds: bears are still adding into strength rather than covering. Short interest ticked up a further 2.1% on Thursday to 5.9% of free float, bringing the weekly gain in borrowed shares to 8.5%. That marks a meaningful escalation from the 7.4% weekly rise noted earlier in the week. The cost to borrow has eased slightly to 0.45%, down about 9% on the week, suggesting no incremental strain in the lending market — and availability remains extraordinarily loose at over 2,000% of short interest, meaning roughly twenty shares are available to borrow for every one currently lent out. There is no mechanical squeeze pressure. What looks like a classic short-squeeze setup is, in the lending data, anything but.
Options positioning has actually softened relative to the stock's move. The put/call ratio fell to 1.21 on Friday, just below its 20-day average of 1.23 and half a standard deviation beneath it. That's a notable contrast: despite a 44% weekly gain, options traders are not rushing to protect gains with puts at an unusual rate. If anything, the PCR is more neutral than defensive — a divergence worth watching given how aggressively the stock has moved.
The analyst community is broadly constructive but increasingly trailing the price action. The consensus is Buy with a mean target of $394, only about 4% above Friday's close. Raymond James raised its target to $435 in early July; Citigroup went to $420 in April; but Morgan Stanley holds at Equal-Weight with a $290 target — well below where the stock now trades. JP Morgan's Overweight target of $300 is similarly stale relative to current levels. The bull case rests on structural AI-driven demand for transceivers and data-centre optics buildout. Bears point to exposure to Chinese military-supply-chain risk, uncertainty around co-packaged optics cannibalising revenue, and a valuation — P/E near 30x — that now prices in considerable execution. The stock has nearly doubled year-to-date, and EPS momentum factor scores rank in the 95th–98th percentile, suggesting estimates have been rising sharply; the EPS surprise rank of just 31, however, implies the company does not consistently beat by large margins.
Insider activity leans net-negative on a 90-day basis. The CEO sold over $11 million of stock in early June, and the CFO has trimmed twice since May. The net 90-day insider sales figure is roughly $13.7 million. These are likely pre-scheduled, low-significance trades — ORTEX scores them 1–2 out of 10 — but the directional signal is one-way: nobody at the company has been buying into this rally. Peers have moved sharply too, with FN up 29% and GLW up 20% on the week, suggesting the whole photonics and connectivity complex has re-rated — making it harder to read COHR's move as purely idiosyncratic.
The print will test whether Coherent's Q4 results and forward guidance can justify a valuation that has now run well past most of the Street's price targets, with a short base that has been adding — not cutting — through one of the sharpest weekly moves in the stock's recent history.
Stocks in this article
See the live data behind this article on ORTEX.
Open COHR on ORTEX →How this article was generated
- Generated
- 9 Aug 2026, 04:03
- Data as of
- 9 Aug 2026, 04:00
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.